CTLA4Ig combined with anti-LFA-1 prolongs cardiac allograft survival indefinitely
M Corbascio, H Ekstrand, C Österholm, Z Qi… - Transplant …, 2002 - Elsevier
CTLA4Ig and anti-LFA-1 are members of a new generation of immunomodulatory drugs
which inhibit important signaling pathways in T cell activation. Both substances target
molecules which have pivitol functions in the activation of CD4+ and CD8+ T cells and have
been theorized to have an interdependent relationship. These drugs have been used
independently in various treatment regimens and have shown great promise in prolonging
the survival of allografts. In order to test whether these substances have synergistic or …
which inhibit important signaling pathways in T cell activation. Both substances target
molecules which have pivitol functions in the activation of CD4+ and CD8+ T cells and have
been theorized to have an interdependent relationship. These drugs have been used
independently in various treatment regimens and have shown great promise in prolonging
the survival of allografts. In order to test whether these substances have synergistic or …